As the technological capabilities powering AI-assisted drug discovery advance, startups in the sector are scrambling to explain their edge over conventional LLMs. Over the last 12 months, VC invested a total of $3.2 billion across 135 AI drug development startups, according to a new PitchBook analyst note. And investors have been paying up to do so. The new research found that AI-native biotech companies have recently been fetching a nearly 100% valuation premium over the biopharma valuations more broadly. But in their fundraising efforts, founders say one tall task is explaining to investors the technicalities of how their models differ from off-the-shelf, user-driven LLMs like OpenAI’s ChatGPT.
Read the full article: AI Biotechs Fetch Big Premiums as Investors Pile into Drug Discovery Startups //
Source: https://pitchbook.com/news/articles/ai-biotechs-fetch-big-premiums-as-investors-pile-into-drug-discovery-startups